Tomas P. M.
- Country
- Spain
- Department
- Oncología
Research Overview
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- Evaluation of ERBB2 mRNA Cut-Point for Predicting Trastuzumab Deruxtecan Efficacy in Advanced or Metastatic Cancer Patients
- Efficacy and Safety of Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib in ER+/HER2- Advanced Breast Cancer with ESR1 Mutation
Data & Insights
Has run more than one trial at 194 of 460 partner sites.
Specializations
Breast Oncology
Clinical research in breast cancer includes hormone receptor-positive and HER2-negative disease, HER2-positive malignancies, triple-negative breast cancer, and early-stage, locally advanced, and metastatic settings. The investigator is also involved in studies addressing biomarker-defined subgroups and treatment-resistant disease.
- Advanced breast cancer
- HER2-targeted therapy
- Triple-negative breast cancer
- Early breast cancer
Therapeutic interest extends to precision oncology strategies for patients with molecular alterations such as PIK3CA, BRCA, and ESR1 changes.
Thoracic and Solid Tumor Oncology
The investigator is active in non-small cell lung cancer, small cell lung cancer, and broader solid tumors, including head and neck squamous cell carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma. Research also spans advanced and unresectable disease across multiple tumor types.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck cancer
- Gastrointestinal cancers
Key therapeutic themes include targeted therapy, immunotherapy, and treatment of metastatic solid tumors with actionable molecular features.
Hematologic Malignancies
Research activity covers multiple myeloma, acute myeloid leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and other B-cell and T-cell lymphomas. The portfolio includes both newly diagnosed and relapsed or refractory hematologic cancers.
- Multiple myeloma
- Acute myeloid leukemia
- Lymphoma
- Myelodysplastic syndromes
Therapeutic focus includes cellular therapy, antibody-based treatment, and transplant-related approaches in blood cancers.
Genitourinary and Renal Oncology
Clinical interests include prostate cancer, renal cell carcinoma, urothelial carcinoma, and bladder cancer, with attention to advanced, metastatic, and treatment-resistant disease. The investigator is involved in research on both early and later lines of therapy in these genitourinary tumors.
- Prostate cancer
- Renal cell carcinoma
- Urothelial carcinoma
- Bladder cancer
Relevant therapeutic domains include androgen receptor-targeted therapy, immune checkpoint inhibition, and molecularly guided treatment.
Hepatic, Immune, and Multisystem Disease
The investigator also participates in studies involving liver disease, cirrhosis, primary biliary cholangitis, hepatitis B, autoimmune disease, and inflammatory disorders such as Crohn's disease and ulcerative colitis. Additional interests include cardiovascular disease and neurodegenerative disease.
- Cholestatic and cirrhotic liver disease
- Autoimmune and inflammatory disease
- Cardiovascular disease
- Neurodegenerative disorders
Therapeutic involvement reflects work in organ dysfunction, immune-mediated disease, and symptom-directed treatment across diverse medical areas.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.